Posts Tagged ‘Implantable’

Implandata Ophthalmic Products GmbH

Implandata Ophthalmic Products GmbH AAO 2014

Implandata Ophthalmic Products GmbH is developing a patient-operated, hand-held system, which works with an implantable micro sensor capable of measuring absolute intraocular pressure continuously or on demand. Company Co-founder and General Manager Max G. Ostermeier, MBA, explained that after the patient takes the measurement, the device sends the IOP data via GSM/modem to the patient’s…

Read More

Neurotech

Neurotech AAO 2014

Quinton Oswold, President and CEO of Neurotech Pharmaceuticals Inc., sees huge opportunity both in wet AMD and diabetic macular edema patients who need more extensive and longer lasting therapies. Neurotech’s Encapsulated Cell Technology (ECT) platform provides long-term continuous delivery (2+years) of protein drugs directly into the vitreous of the eye. The company is developing multiple…

Read More

Alimera Sciences

Alimera Sciences

Alimera Sciences Inc. is ready to launch in the US its recently approved intravitreal implant, Iluvien, for treating diabetic macular edema. President and CEO Dan Myers reported the company has a direct sales force of 32 reps ready for the product’s commercial debut in Q1 2015. Iluvien delivers a corticosteroid, providing sustained therapeutic effect for…

Read More

Device, Delivery, & Diagnostic Company Showcase

Device, Delivery, & Diagnostic Company Showcase

Chicago—The 6th Annual Ophthalmology Innovation Summit (OIS), held here prior to the annual American Academy of Ophthalmology (AAO) featured a plethora of intriguing early- to mid-stage companies focused in the medical devices arena. A regular presenter in past OIS meetings has been Tom Frinzi, President and CEO of WaveTec Vision (Aliso Viejo, California). Frinzi has…

Read More

Next Generation Ocular Drug Delivery Platforms

Next Generation Ocular Drug Delivery Platforms

The human eye measures approximately one inch in diameter, but traversing that blink-of-an-eye distance to achieve safe, effective and stable delivery of ophthalmology drugs via minimally or non-invasive medical devices to treat major eye diseases has taken more than 40 years to accomplish. Is the wait for a Holy Grail product in ophthalmology medical technology…

Read More

2013 Ophthalmic Market – “Year in Review”

2013 Ophthalmic Market – “Year in Review”

Emmett T. Cunningham Jr. MD PhD MPH, Partner at Clarus Ventures and Summit Chairman, delivers an overview of some ophthalmic highlights from 2013. Sharing key accomplishments from many device and pharma companies, Emmett continues to expand on the present landscape with promising data to show that the ophthalmology market is stable despite the decrease in…

Read More

Neurotech Transforms the Delivery of Biologics

Neurotech Transforms the Delivery of Biologics

Ted Danse, President & CEO for Neurotech, begins by touching upon their ETC technology platform, labeling it as “transformational” in its ability to deliver biologics over multiple years with one simple and minimally invasive procedure. Continuing to detail the key components of their program, Ted expands on the company’s progress thus far. Presenter: Edward (Ted)…

Read More